Application for approval of CPP-1X/sul for the treatment of familial adenomatous polyposis (FAP) submitted to the European Medicines Agency

CPP-1X/sul is a combination of eflornithine and sulindac. The application includes data from a Phase III study (FAP-310; n=171), comparing the combination to each drug alone (no better overall but suggested benefit vs single agents in delaying lower GI surgical events).


Biospace Inc.